Derenzini M - Search Results

1

Derenzini M, Montanaro L, Trerè D. Derenzini M, et al. Acta Histochem. 2017 Apr;119(3):190-197. doi: 10.1016/j.acthis.2017.01.009. Epub 2017 Feb 3. Acta Histochem. 2017. PMID: 28168996 Review.

2

Increased mortality rate and not impaired ribosomal biogenesis is responsible for proliferative defect in dyskeratosis congenita cell lines.

Montanaro L, Chillà A, Trerè D, Pession A, Govoni M, Tazzari PL, Derenzini M. Montanaro L, et al. Among authors: derenzini m. J Invest Dermatol. 2002 Jan;118(1):193-8. doi: 10.1046/j.0022-202x.2001.01634.x. J Invest Dermatol. 2002. PMID: 11851894 Free article.

3

Nucleolus, ribosomes, and cancer.

Montanaro L, Treré D, Derenzini M. Montanaro L, et al. Among authors: derenzini m. Am J Pathol. 2008 Aug;173(2):301-10. doi: 10.2353/ajpath.2008.070752. Epub 2008 Jun 26. Am J Pathol. 2008. PMID: 18583314 Free PMC article. Review.

4

Relationship between dyskerin expression and telomerase activity in human breast cancer.

Montanaro L, Calienni M, Ceccarelli C, Santini D, Taffurelli M, Pileri S, Treré D, Derenzini M. Montanaro L, et al. Among authors: derenzini m. Cell Oncol. 2008;30(6):483-90. doi: 10.3233/clo-2008-0436. Cell Oncol. 2008. PMID: 18936525 Free PMC article.

5

Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation.

Montanaro L, Calienni M, Bertoni S, Rocchi L, Sansone P, Storci G, Santini D, Ceccarelli C, Taffurelli M, Carnicelli D, Brigotti M, Bonafè M, Treré D, Derenzini M. Montanaro L, et al. Among authors: derenzini m. Cancer Res. 2010 Jun 1;70(11):4767-77. doi: 10.1158/0008-5472.CAN-09-4024. Epub 2010 May 25. Cancer Res. 2010. PMID: 20501855

6

Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential.

Montanaro L, Treré D, Derenzini M. Montanaro L, et al. Among authors: derenzini m. Biochim Biophys Acta. 2012 Jan;1825(1):101-10. doi: 10.1016/j.bbcan.2011.10.006. Epub 2011 Nov 3. Biochim Biophys Acta. 2012. PMID: 22079382 Review.

7

Ribosome biogenesis and control of cell proliferation: p53 is not alone.

Donati G, Montanaro L, Derenzini M. Donati G, et al. Among authors: derenzini m. Cancer Res. 2012 Apr 1;72(7):1602-7. doi: 10.1158/0008-5472.CAN-11-3992. Epub 2012 Jan 26. Cancer Res. 2012. PMID: 22282659

8

Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

Brighenti E, Treré D, Derenzini M. Brighenti E, et al. Among authors: derenzini m. Oncotarget. 2015 Nov 17;6(36):38617-27. doi: 10.18632/oncotarget.5775. Oncotarget. 2015. PMID: 26415219 Free PMC article. Review.

9

Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate.

Brighenti E, Giannone FA, Fornari F, Onofrillo C, Govoni M, Montanaro L, Treré D, Derenzini M. Brighenti E, et al. Among authors: derenzini m. Oncotarget. 2016 Sep 27;7(39):63226-63241. doi: 10.18632/oncotarget.11441. Oncotarget. 2016. PMID: 27557515 Free PMC article.

10

The pre-existing population of 5S rRNA effects p53 stabilization during ribosome biogenesis inhibition.

Onofrillo C, Galbiati A, Montanaro L, Derenzini M. Onofrillo C, et al. Among authors: derenzini m. Oncotarget. 2017 Jan 17;8(3):4257-4267. doi: 10.18632/oncotarget.13833. Oncotarget. 2017. PMID: 28032591 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page